BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28207739)

  • 1. Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression.
    Zhang M; Qin Y; Zuo B; Gong W; Zhang S; Gong Y; Quan Z; Chu B
    PLoS One; 2017; 12(2):e0167782. PubMed ID: 28207739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of Notch-regulated Ankyrin Repeat Protein Exerts Antitumor Activities against Growth of Thyroid Cancer.
    Chu BF; Qin YY; Zhang SL; Quan ZW; Zhang MD; Bi JW
    Chin Med J (Engl); 2016 Jul; 129(13):1544-52. PubMed ID: 27364790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
    Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
    J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.
    Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Xin S; Zhang J
    BMC Cancer; 2020 Nov; 20(1):1143. PubMed ID: 33238942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
    Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
    Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma.
    Lv N; Shan Z; Gao Y; Guan H; Fan C; Wang H; Teng W
    Endocrine; 2016 Mar; 51(3):469-77. PubMed ID: 26289126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
    Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
    Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
    Wang Z; Zhang H; Zhang P; Dong W; He L
    Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression and role of serum response factor in papillary carcinoma of the thyroid.
    Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
    Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis identifies DUSP5 as a novel prognostic indicator for thyroid follicular carcinoma.
    Zhang Q; Xing Y; Jiang S; Xu C; Zhou X; Zhang R; Xie T; Zou Z; Gong P; Zhu H; Zhang D; Ma H; Liao L; Dong J
    Thorac Cancer; 2020 Feb; 11(2):336-345. PubMed ID: 31821724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling.
    Jarrett SM; Seegar TCM; Andrews M; Adelmant G; Marto JA; Aster JC; Blacklow SC
    Sci Signal; 2019 Nov; 12(606):. PubMed ID: 31690634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma.
    Xu W; Wang L; An Y; Ye J
    Med Sci Monit; 2019 May; 25():3762-3770. PubMed ID: 31107859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
    Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
    Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
    Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
    Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
    Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
    World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of the ESR1 Gene and ESR Ratio (ESR1/ESR2) is Associated with a Worse Prognosis in Papillary Thyroid Carcinoma: The Impact of the Estrogen Receptor α/β Expression on Clinical Outcomes in Papillary Thyroid Carcinoma Patients.
    Yi JW; Kim SJ; Kim JK; Seong CY; Yu HW; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2017 Nov; 24(12):3754-3762. PubMed ID: 28124274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
    Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
    J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.